

Elagolix/ estradiol/ norethindrone (Oriahnn)

Coverage Criteria:

1. The patient will use Orihann for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women, AND
2. The patient is 18 years of age and older, AND
3. Prescribed by or in consultation with OB/GYN, AND
4. The patient has tried and failed or has a contraindication to at least two of the following:
 - a. Preferred (oral or vaginal) contraceptives (two contraceptives is an acceptable trial/failure);
 - b. Levonorgestrel intra-uterine device (IUD);
 - c. Oral tranexamic acid; AND
5. Surgical intervention has been discussed and is not an appropriate treatment option or patient declines, AND
6. Prescribed within the FDA approved regimen

Coverage Duration:

6 months initial, 18 months renewal

Renewal Criteria:

1. Physician attestation of improvement of heavy menstrual bleeding, AND
2. Prescribed within the FDA approved regimen